Chapter-22

Addressing the Relationship between Diabetes and Cancer - Future Health Strategies

Authors

Dr. Sanjeev Kumar
Department of Zoology
B.M. College, Rahika, L.N.
Mithila University, Darbhanga, Bihar, India.
E-mail; sanjeev.kdbg@gmail.com;

Dr. Kumari Shachi
Department of Zoology
K.S. College, Laheriasarai, L.N.
Mithila University, Darbhanga, Bihar, India.

Abstract

This chapter explores the intricate relationship between diabetes and cancer, two prevalent chronic diseases that pose significant challenges to global health. Epidemiological evidence suggests a bidirectional association between diabetes and cancer, with individuals with diabetes being at increased risk of certain cancers, while cancer diagnosis and treatment may influence glycemic control and diabetes management. The underlying biological mechanisms linking diabetes and cancer include hyperinsulinemia, insulin resistance, chronic inflammation, dysregulated glucose metabolism, and shared risk factors such as obesity and physical inactivity. Understanding these mechanisms is crucial for developing targeted interventions and personalized treatment strategies that address both conditions simultaneously.Future health strategies aimed at addressing the relationship between diabetes and cancer should focus on several key areas. These include optimizing diabetes management to reduce cancer risk and improve cancer outcomes, implementing cancer screening and prevention programs tailored to individuals with diabetes, integrating multidisciplinary care approaches to address the complex needs of patients with both diabetes and cancer, and leveraging advances in precision medicine and molecular diagnostics to identify novel therapeutic targets and improve treatment outcomes.

Keywords: Diabetes, Cancer, Hyperinsulinemia, Insulin Resistance, Inflammation, Glycemic Control

****

1. INTRODUCTION

In recent years, the intricate interplay between diabetes and cancer has come to the forefront of medical research, challenging the traditional silos that once separated these two complex conditions. The association between diabetes and an increased risk of certain cancers has raised critical questions about shared pathways, common risk factors, and potential novel strategies for prevention and management. This chapter delves into the evolving landscape of understanding the interrelationship between diabetes and cancer, exploring future health strategies that promise a more integrated and effective approach.Both diabetes and cancer are prevalent chronic diseases with substantial global health burdens. Studies have consistently shown that individuals with diabetes face a higher risk of developing certain cancers, including breast, colorectal, pancreatic, and liver cancer. The shared risk factors such as obesity, inflammation, and insulin resistance have sparked interest in unraveling the molecular mechanisms connecting these seemingly distinct conditions [1].

Insulin, a hormone crucial for glucose metabolism, also plays a role in cell growth and survival. In individuals with insulin resistance, a hallmark of type 2 diabetes, there is an excess of insulin in circulation. This heightened insulin level, along with insulin-like growth factors, can stimulate cell proliferation and inhibit apoptosis, contributing to the initiation and progression of cancer.Chronic inflammation, a common denominator in both diabetes and cancer, creates a microenvironment conducive to tumor development. Immune dysfunction, often observed in diabetes, further exacerbates the risk of cancer by impairing the body's ability to detect and eliminate abnormal cells. Future health strategies must address these inflammatory processes to mitigate the dual burden of diabetes and cancer.

2. FUTURE HEALTH STRATEGIES

Advancements in genomic and molecular profiling offer opportunities for precision medicine in the management of diabetes-cancer comorbidity. Tailoring treatment approaches based on individual genetic makeup and molecular signatures may enhance therapeutic efficacy and reduce side effects. Integrating precision medicine into clinical practice requires collaborative efforts between oncologists and endocrinologists.Promoting healthy lifestyle

choices, including regular physical activity and a balanced diet, remains a cornerstone in preventing both diabetes and cancer. Future health strategies should focus on comprehensive interventions targeting modifiable risk factors like obesity and sedentary behavior. Community-based programs, education, and support systems can empower individuals to adopt and sustain healthy behaviors.

Exploring the intersection of cancer immunotherapy and metabolic modulation presents an intriguing avenue for future research. Harnessing the immune system to target cancer cells while simultaneously addressing metabolic dysregulation in diabetes holds promise for innovative treatment strategies. Combining immunotherapies with metabolic modulators could provide synergistic benefits, improving outcomes for individuals with diabetes and cancer.

Developing integrated care models that bridge the gap between diabetes and cancer management is crucial. Coordinated efforts between healthcare providers, multidisciplinary teams, and patient support networks can optimize preventive measures, early detection, and treatment strategies. Such models should prioritize seamless communication and shared decision-making to deliver holistic and patient-centered care [5,6,7].

Several Types of Cancer have demonstrated a Significant Relationship with Diabetes. Some of the Notable Associations Include

1. Connection between Diabetes and Pancreatic Cancer

Diabetes and pancreatic cancer share a complex and intriguing relationship that has captured the attention of researchers and clinicians alike. This dictation delves into the intricate interplay between these two conditions, exploring the bidirectional nature of their association, common risk factors, and the implications for early detection and management.

The link between diabetes and pancreatic cancer is well-established, with diabetes serving as both a risk factor and a potential early indicator of pancreatic malignancies. Studies have consistently shown that individuals with long-standing diabetes face an increased risk of developing pancreatic cancer. The exact mechanisms underlying this association are multifaceted, involving factors such as insulin resistance, chronic inflammation, and hormonal imbalances [3].

Insulin resistance, a hallmark of type 2 diabetes, plays a pivotal role in the development of pancreatic cancer. Elevated insulin levels can stimulate cell

proliferation and inhibit apoptosis, creating an environment conducive to tumor initiation and progression. The chronic inflammatory state associated with diabetes further contributes to the promotion of pancreatic cancer [11,12,13].

In a unique bidirectional relationship, pancreatic cancer can also induce diabetes. The tumor's presence in the pancreas can disrupt the organ's normal functioning, impacting insulin production and secretion. As a result, individuals may experience diabetes as an early symptom of pancreatic cancer. This underlines the importance of recognizing new-onset diabetes as a potential marker for pancreatic malignancies, prompting further investigation and diagnostic assessments.

Both diabetes and pancreatic cancer share certain risk factors, creating a synergistic effect that heightens the likelihood of co-occurrence. Obesity, a well-known risk factor for type 2 diabetes, is also associated with an increased risk of pancreatic cancer. Lifestyle factors such as a sedentary lifestyle and poor dietary choices contribute to the development of both conditions.

Common pathways involving insulin, inflammation, and cellular growth further underscore the intricate relationship. Understanding these shared mechanisms is crucial for developing targeted interventions that address the root causes of both diabetes and pancreatic cancer.Recognizing the connection between diabetes and pancreatic cancer holds significant implications for early detection and improved patient outcomes. Individuals with long-standing diabetes may benefit from enhanced screening protocols for pancreatic cancer, enabling earlier diagnosis and intervention.As research in this field progresses, future directions include investigating novel biomarkers, exploring advanced imaging techniques, and developing personalized treatment approaches. The integration of multidisciplinary care involving endocrinologists, oncologists, and researchers is essential for unraveling the complexities of this relationship and advancing strategies for prevention, early detection, and effective management.

2. Association between Type 2 Diabetes and Colorectal Cancer Risk

Type 2 diabetes mellitus (T2DM) and colorectal cancer (CRC) are two significant health burdens globally, with increasing prevalence rates. Over the years, researchers have uncovered a compelling association between these seemingly unrelated conditions. Numerous studies have consistently demonstrated that individuals with T2DM face a higher risk of developing CRC compared to those without diabetes. This essay aims to delve into the evidence supporting this association, explore potential underlying mechanisms, and discuss the clinical implications of this relationship [2].

Epidemiological Evidence: Epidemiological studies have played a crucial role in elucidating the link between T2DM and CRC risk. Large-scale cohort studies, meta-analyses, and systematic reviews have consistently reported a positive association between these two conditions. For instance, a meta-analysis by Larsson et al. (2005) found that individuals with T2DM have a 30-40% higher risk of CRC compared to non-diabetic individuals. Similarly, a cohort study conducted by Lee et al. (2011) observed a significant association between T2DM duration and CRC risk, with longer diabetes duration correlating with higher CRC incidence rates.

Underlying Mechanisms: Several biological mechanisms have been proposed to explain the increased risk of CRC in individuals with T2DM. One of the primary mechanisms is insulin resistance and hyperinsulinemia, hallmark features of T2DM. Insulin, besides its role in glucose metabolism, also functions as a growth factor and has mitogenic properties. Chronic hyperinsulinemia can promote cell proliferation, inhibit apoptosis, and stimulate the production of insulin-like growth factors (IGFs), all of which contribute to carcinogenesis.

Furthermore, chronic low-grade inflammation, commonly observed in individuals with T2DM, has been implicated in CRC development. Pro-inflammatory cytokines and adipokines released from adipose tissue in obesity and insulin resistance create a tumor-promoting microenvironment. Additionally, dysregulated lipid metabolism and alterations in gut microbiota composition in individuals with T2DM may also contribute to CRC risk.

Clinical Implications: Understanding the association between T2DM and CRC has important clinical implications. Healthcare providers should be aware of the heightened CRC risk in individuals with T2DM and consider incorporating cancer screening and prevention strategies into their diabetes management plans. Current screening guidelines recommend colonoscopy starting at age 50 for average-risk individuals. However, individuals with T2DM may benefit from earlier and more frequent screening due to their increased risk.

Moreover, lifestyle modifications, including weight management, regular physical activity, and a healthy diet, are crucial for reducing both T2DM and CRC risk. Patients with T2DM should be educated about the importance of these lifestyle factors and encouraged to adopt healthy behaviors. Pharmacological interventions targeting insulin resistance and inflammation may also hold promise in reducing CRC risk in individuals with T2DM.

In conclusion, the evidence linking T2DM to an increased risk of CRC is robust and consistent across various studies. The underlying mechanisms

involving insulin resistance, inflammation, and other metabolic abnormalities provide insights into the biological basis of this association. Recognizing the elevated CRC risk in individuals with T2DM is essential for effective preventive strategies and early detection through screening. Addressing modifiable risk factors and promoting healthy lifestyles are crucial steps in mitigating the burden of both T2DM and CRC in affected populations. Further research is warranted to explore additional mechanistic links and develop targeted interventions for reducing CRC risk in individuals with T2DM.

3. Complex Relationship between Diabetes and Breast Cancer in Postmenopausal Women

The intersection between diabetes and breast cancer has long intrigued researchers, unveiling a complex relationship influenced by multifaceted factors. Particularly noteworthy is the distinct susceptibility observed in postmenopausal women with type 2 diabetes, where the risk of developing specific breast cancer subtypes appears heightened. This essay delves into the intricacies of this association, highlighting its variability by subtype and the implications for clinical practice and further research.

Firstly, it's essential to acknowledge the diverse biological pathways intertwining diabetes and breast cancer. Hormonal imbalances, notably elevated insulin and estrogen levels, characterize both conditions and are implicated in tumorigenesis. Postmenopausal women, whose estrogen levels decrease, may exhibit altered dynamics in this interplay, influencing the risk of certain breast cancer subtypes, such as hormone receptor-positive tumors.

Insulin resistance, a hallmark of type 2 diabetes, adds another layer of complexity. It fosters a pro-inflammatory environment conducive to cancer development and progression. Consequently, postmenopausal women with diabetes face a unique milieu that potentially amplifies their breast cancer risk, especially for subtypes driven by inflammatory processes or insulin-like growth factors.

Furthermore, the shared risk factors between diabetes and breast cancer contribute to their intertwined pathophysiology. Obesity, sedentary lifestyle, and dietary habits are common denominators predisposing individuals to both conditions. Addressing these modifiable risk factors emerges as a pivotal strategy in mitigating the risk of breast cancer among postmenopausal women with type 2 diabetes.

Subtype specificity emerges as a critical aspect in understanding this intricate relationship. While some studies suggest a predilection for hormone

receptor-positive breast cancers, others hint at associations with triple-negative tumors. This heterogeneity underscores the necessity for tailored screening protocols and treatment approaches, considering the varying biological underpinnings of different breast cancer subtypes.

In clinical practice, healthcare providers must remain vigilant in assessing breast cancer risk among postmenopausal women with type 2 diabetes. Enhanced surveillance protocols, including regular breast screenings and comprehensive metabolic evaluations, are imperative for early detection and intervention. Moreover, personalized lifestyle interventions targeting obesity management and glycemic control hold promise in attenuating the risk of breast cancer in this vulnerable population.

Nevertheless, gaps persist in our understanding of the intricate interplay between diabetes and breast cancer. Further research endeavors are warranted to unravel the underlying mechanisms driving subtype-specific associations and identify novel therapeutic targets. Longitudinal studies elucidating the temporal relationship between diabetes onset, metabolic perturbations, and subsequent breast cancer development are particularly warranted.

In conclusion, the association between diabetes and breast cancer in postmenopausal women epitomizes a complex interplay shaped by hormonal, metabolic, and lifestyle factors. Understanding the nuanced dynamics of this relationship is pivotal for refining risk stratification strategies and informing personalized interventions. By unraveling the intricacies of this intersection, we move closer to unraveling the mysteries of both diabetes and breast cancer, ultimately paving the way for more effective prevention and management approaches.

4. Unveiling the Hormonal Interplay: Exploring the Link between Diabetes and Breast Cancer

The intricate relationship between diabetes and breast cancer unveils a compelling narrative intricately woven by shared hormonal factors, notably insulin and estrogen. This essay delves into the profound impact of these hormones on the interplay between diabetes and breast cancer, elucidating their multifaceted roles and implications for both prevention and treatment strategies [8].

Firstly, insulin emerges as a central player in this complex narrative. In the context of diabetes, insulin resistance ensues, leading to dysregulated insulin levels. This hyperinsulinemia not only contributes to the pathogenesis of diabetes but also exerts profound effects on tumorigenesis. Insulin serves as a

potent mitogen, promoting cell proliferation and inhibiting apoptosis, thereby fostering an environment conducive to cancer development and progression.

Moreover, insulin exerts indirect effects through its interaction with insulin-like growth factor 1 (IGF-1), a growth-promoting hormone. Elevated levels of IGF-1, often observed in individuals with insulin resistance, further potentiate tumor growth by activating downstream signaling pathways involved in cell proliferation and survival. Thus, the dysregulation of insulin and IGF-1 axis forms a critical link between diabetes and breast cancer, particularly in postmenopausal women where estrogen levels decline, rendering insulin-mediated pathways more prominent [9].

Concurrently, estrogen, a quintessential hormone in breast cancer pathophysiology, adds another layer of complexity to this narrative. In postmenopausal women, adipose tissue becomes the primary source of estrogen production, as ovarian estrogen synthesis wanes. Obesity, a common comorbidity in individuals with diabetes, contributes to estrogen excess through aromatase-mediated conversion of androgens to estrogen in adipocytes.

Elevated estrogen levels, coupled with insulin resistance, create a synergistic milieu fostering breast cancer development. Estrogen receptors (ER) play a pivotal role in this process, with estrogen-driven signaling pathways promoting cell proliferation and survival in ER-positive breast cancer subtypes. Consequently, postmenopausal women with diabetes may face an augmented risk of developing ER-positive breast tumors, underscoring the intricate interplay between hormonal dysregulation and breast cancer susceptibility.

Furthermore, the crosstalk between insulin and estrogen signaling pathways amplifies the oncogenic potential of both hormones. Insulin potentiates estrogen synthesis by upregulating aromatase activity, while estrogen enhances insulin sensitivity, thereby perpetuating a vicious cycle of hormonal dysregulation and tumorigenesis.

In clinical practice, understanding the intertwined roles of insulin and estrogen is pivotal for devising tailored prevention and treatment strategies. Lifestyle interventions targeting obesity and insulin resistance emerge as cornerstone approaches in mitigating breast cancer risk among individuals with diabetes. Additionally, pharmacological interventions targeting hormonal pathways, such as insulin sensitizers and aromatase inhibitors, hold promise in disrupting the hormonal milieu conducive to breast cancer development [10].

In conclusion, shared hormonal factors, notably insulin and estrogen, intricately link diabetes and breast cancer, shaping their intersecting

pathophysiology. The dysregulation of insulin and estrogen signaling pathways fosters a synergistic environment fueling tumorigenesis, particularly in postmenopausal women with type 2 diabetes. By unraveling the complexities of this hormonal interplay, we pave the way for targeted interventions aimed at mitigating breast cancer risk and improving clinical outcomes in this vulnerable population.

5. Non-Alcoholic Fatty Liver Disease (NAFLD) and Its Association with Diabetes

Non-Alcoholic Fatty Liver Disease (NAFLD): Non-Alcoholic Fatty Liver Disease (NAFLD) is a prevalent condition characterized by excessive fat accumulation in the liver, not caused by alcohol consumption. It encompasses a spectrum of liver abnormalities, ranging from simple fatty liver (steatosis) to more severe forms such as non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and even hepatocellular carcinoma (HCC). NAFLD is now recognized as a leading cause of chronic liver disease worldwide, with its prevalence mirroring the global epidemic of obesity and metabolic syndrome.

Association with Diabetes: NAFLD is closely associated with type 2 diabetes mellitus (T2DM) and insulin resistance. Epidemiological studies have consistently shown a high prevalence of NAFLD among individuals with diabetes, with estimates ranging from 50% to 75% in diabetic populations. Conversely, patients with NAFLD have a significantly higher prevalence of diabetes compared to those without liver involvement. This bidirectional relationship underscores the intricate interplay between metabolic dysregulation, hepatic lipid metabolism, and insulin resistance in the pathogenesis of both diseases.

Statement of Purpose and Scope of the Paper: This paper aims to elucidate the complex relationship between NAFLD and diabetes, with a specific focus on their mutual impact on liver health and the heightened risk of liver cancer. By synthesizing current evidence from epidemiological studies, clinical trials, and mechanistic investigations, the paper seeks to address the following objectives:

1. Investigate the epidemiological link between NAFLD, diabetes, and liver cancer, including prevalence data and risk stratification in affected populations.
2. Examine the pathophysiological mechanisms underlying the association between NAFLD and diabetes, with a particular emphasis on insulin resistance, hepatic lipid metabolism, inflammation, and fibrosis.

3. Explore the clinical implications of NAFLD in diabetic patients, including diagnostic challenges, disease progression, and management strategies aimed at mitigating liver-related complications and reducing liver cancer risk.
4. Discuss emerging research trends and future directions in the field, highlighting opportunities for preventive interventions, novel therapeutic targets, and multidisciplinary approaches to address the growing burden of NAFLD-related liver disease in diabetic populations.

Through a comprehensive review and analysis of existing literature, this paper intends to enhance our understanding of NAFLD-diabetes comorbidity and its implications for clinical practice, public health policy, and research initiatives aimed at combating liver cancer and related complications.

The Intricate Relationship between Diabetes and Endometrial Cancer has emerged as a significant area of research, captivating the attention of scientists, clinicians, and public health professionals alike. This comprehensive exploration aims to unravel the complex interplay between these two conditions, examining the bidirectional association, shared risk factors, and the implications for prevention, early detection, and management.

The association between diabetes and endometrial cancer is particularly pronounced, with numerous studies highlighting diabetes as a significant risk factor for the development of this gynecological malignancy. Postmenopausal women with type 2 diabetes exhibit an elevated risk of endometrial cancer compared to their non-diabetic counterparts [4].

Insulin resistance, a central feature of type 2 diabetes, is a key player in this association. Elevated insulin levels, a consequence of insulin resistance, may stimulate the growth of endometrial cells and increase the risk of cancer. Moreover, the imbalance of sex hormones, including elevated levels of estrogen, further contributes to the development and progression of endometrial cancer in individuals with diabetes.

In a reciprocal relationship, endometrial cancer can also influence the development of diabetes. The systemic effects of cancer, such as inflammation and metabolic disturbances, may impact glucose metabolism and lead to the onset of diabetes. Recognizing new-onset diabetes in individuals diagnosed with endometrial cancer emphasizes the need for vigilant monitoring and integrated healthcare approaches.

Beyond the direct association, diabetes and endometrial cancer share common risk factors and hormonal influences. Obesity, a known risk factor for type 2 diabetes, is also strongly associated with an increased risk of endometrial

cancer. The intricate interplay of obesity, insulin resistance, and hormonal imbalances creates a synergistic effect, amplifying the susceptibility to both conditions.

Chronic inflammation, a common denominator in diabetes and cancer, plays a pivotal role in the development of endometrial cancer. Inflammatory processes contribute to the promotion of tumor growth and angiogenesis within the endometrium. Hyperinsulinemia, resulting from insulin resistance, further exacerbates this process by fostering cellular proliferation and inhibiting apoptosis.

Advancements in molecular biology have unveiled intricate molecular mechanisms linking diabetes and endometrial cancer. Shared genetic factors and signaling pathways provide insights into the interconnected nature of these conditions. Unraveling the genetic underpinnings holds promise for targeted therapies and personalized interventions.

Given the established association between diabetes and endometrial cancer, there is a pressing need for effective screening and early detection strategies. Tailored screening protocols for women with diabetes, especially those postmenopausal, may facilitate the identification of endometrial abnormalities at an earlier, more treatable stage. Integrated care models involving gynecologists, endocrinologists, and oncologists can optimize surveillance and enhance early intervention.The shared risk factors of obesity and sedentary lifestyle underscore the importance of lifestyle interventions in mitigating the risk of both diabetes and endometrial cancer. Comprehensive programs promoting healthy dietary choices, regular physical activity, and weight management are essential components of prevention strategies. Behavioral changes at the individual and community levels can contribute to a reduction in the incidence of these interconnected conditions.

Understanding the hormonal influences in the diabetes-endometrial cancer relationship opens avenues for innovative therapeutic approaches. Hormone therapies, including those targeting estrogen receptors, may prove effective in certain cases. Moreover, targeted treatments based on the molecular profile of tumors offer personalized and precise interventions, heralding a new era in the management of endometrial cancer in individuals with diabetes.The exploration of the relationship between diabetes and endometrial cancer is an evolving journey, marked by significant discoveries and ongoing research endeavors. Future directions in this field include advancing our understanding of genetic factors, refining screening protocols, and developing targeted therapies based on individualized patient profiles. The intricate interplay between diabetes and endometrial cancer demands a holistic approach that

spans across disciplines. Collaboration between endocrinologists, gynecologists, oncologists, and researchers is essential for unlocking the mysteries of this relationship and translating findings into actionable strategies for prevention, early detection, and optimal patient care [14,15].

3. CONCLUSION

As the intricate relationship between diabetes and cancer unfolds, future health strategies must embrace a holistic and interdisciplinary approach. Addressing common risk factors, leveraging precision medicine, promoting lifestyle interventions, exploring innovative therapies, and implementing integrated care models are essential steps toward a future where individuals with diabetes and cancer can receive comprehensive and personalized care. Through collaborative research and a commitment to improving patient outcomes, the healthcare community can navigate the complex intersection of these prevalent chronic conditions.

REFERENCES

[1] Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., ... & Pollak, M. (2010). Diabetes and cancer: a consensus report. Diabetes care, 33(7), 1674-1685.

[2] Johnson, J. A., Bowker, S. L., & Richardson, K. (2011). Marra, C. A., & Grant, D. M. Time-varying incidence of cancer after the onset of type 2 diabetes: evidence of potential detection bias. Diabetologia, 54(9), 2263-2271.

[3] Li, D., & Yeung, S. C. (2017). Hassan, M. M., & Li, D. (2013). Diabetes and pancreatic cancer. Molecular carcinogenesis, 51(1), 64-74.

[4] Vigneri, P., Frasca, F., & Sciacca, L. (2009). Diabetes and cancer. Endocrine-related cancer, 16(4), 1103-1123.

[5] Jee, S. H., Ohrr, H., Sull, J. W., Yun, J. E., & Ji, M. (2005). Samet, J. M., & Yun, J. E. (2005). Fasting serum glucose level and cancer risk in Korean men and women. JAMA, 293(2), 194-202.

[6] Barone, B. B., Yeh, H. C., Snyder, C. F., Peairs, K. S., Stein, K. B., Derr, R. L., ... & Brancati, F. L. (2008). Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA, 300(23), 2754-2764.

[7] Habib, S. L., & Rojna, M. (2015). Diabetes and risk of cancer. ISRN oncology, 2013.

[8] Richardson, L. C., Pollack, L. A., Hawkins, N. A., Smith, J. L., Hayes, N., Foster, S. L., ... & Hohman, K. (2011). Diagnosis and initial treatment of breast cancer among women with Medicaid, 2005–2007. American Journal of Public Health, 101(10), 2031-2038.

[9] Carstensen, B., Read, S. H., Friis, S., Sund, R., & Keskimäki, I. (2012). Diabetes and cancer research resources. Pharmacoepidemiology and Drug Safety, 21(Suppl 2), 180-188.

[10] Aggarwal, G., & Kamada, P. (2012). Cholesterol, diabetes and cancer: is there a link?. Trends in endocrinology & metabolism, 23(8), 365-372.

[11] Ruiter, R., Visser, L. E., van Herk-Sukel, M. P., Coebergh, J. W., Haak, H. R., Geelhoed-Duijvestijn, P. H., ... & Stricker, B. H. (2012). Risk of cancer in patients on

insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study. Diabetologia, 55(1), 51-62.
[12] Currie, C. J., Poole, C. D., Gale, E. A., The influence of glucose-lowering therapies on cancer risk in type 2 diabetes (2010). Diabetologia, 53(9), 1639-1645.
[13] Han, X., & Li, J. (2017). Bragazzi, N. L., & Wu, Q. J. (2014). New insights into the risk of cancer associated with diabetes: a systematic review and meta-analysis of 21 cohort studies involving 85, 557 cases. Journal of diabetes and its complications, 28(5), 585-593.
[14] Tsilidis, K. K., Kasimis, J. C., Lopez, D. S., Ntzani, E. E., & Ioannidis, J. P. (2015). Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. Bmj, 350, g7607.
[15] Tseng, C. H. (2011). Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan. Diabetologia, 54(8), 2009-2015.